Sybille Krauss

TL;DR: A potential beneficial role of biguanides such as metformin in the prophylaxis and/or therapy of AD is suggested.

TL;DR: It is shown that mutation of MID1 leads to a marked accumulation of the catalytic subunit of protein phosphatase 2A (PP2Ac), a central cellular regulator, which causes hypophosphorylation of MAPs, a pathological mechanism consistent with the OS phenotype.

TL;DR: The data implicate Stat3‐mediated astrogliosis as an important therapeutic target in AD and suggest protective effects on network dysfunction and cognition were recapitulated in APP/PS1 mice systemically treated with a preclinical Stat3 inhibitor drug.

TL;DR: An early pattern of circuit dysregulation in the visual cortex is revealed - one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons, and the antidiabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both early network activity patterns and behavioral aberrations.

TL;DR: It is suggested that a decreased antioxidative capacity and increased susceptibility towards oxidative stress contributes to neuronal cell death in SCA3 and that ATXN3 plays an important role in regulating the FOXO4-dependent antioxidant stress response via SOD2.